home / stock / gnta / gnta quote
Last: | $4.51 |
---|---|
Change Percent: | -3.04% |
Open: | $4.74 |
Close: | $4.51 |
High: | $4.75 |
Low: | $4.1381 |
Volume: | 37,311 |
Last Trade Date Time: | 07/19/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$4.51 | $4.74 | $4.51 | $4.75 | $4.1381 | 37,311 | 07-19-2024 |
$4.6 | $3.6 | $4.6 | $5.87 | $3.6 | 544,442 | 07-18-2024 |
$3.63 | $3.86 | $3.63 | $3.86 | $3.63 | 967 | 07-17-2024 |
$3.69 | $3.6 | $3.69 | $3.87 | $3.5 | 5,808 | 07-16-2024 |
$3.6 | $3.5 | $3.6 | $3.6 | $3.3 | 11,667 | 07-15-2024 |
$3.32 | $3.27 | $3.32 | $3.32 | $3.25 | 2,542 | 07-12-2024 |
$3.42 | $3.03 | $3.42 | $3.424 | $3.03 | 1,235 | 07-11-2024 |
$2.93 | $3.29 | $2.93 | $3.49 | $2.93 | 2,174 | 07-10-2024 |
$3.2278 | $0 | $3.2278 | $0 | $0 | 4 | 07-09-2024 |
$3.2278 | $3.22 | $3.2278 | $3.26 | $2.79 | 2,203 | 07-08-2024 |
$3.0936 | $0 | $3.0936 | $0 | $0 | 156 | 07-05-2024 |
$3.0936 | $3.3 | $3.0936 | $3.3 | $3.0936 | 665 | 07-02-2024 |
$3.083 | $3.1 | $3.083 | $3.12 | $3.06 | 4,641 | 07-01-2024 |
$3.1 | $3.12 | $3.1 | $3.12 | $3.1 | 1,994 | 06-28-2024 |
$3.11 | $3.16 | $3.11 | $3.3 | $3.11 | 3,948 | 06-27-2024 |
$3.34 | $0 | $3.34 | $0 | $0 | 76 | 06-26-2024 |
$3.34 | $0 | $3.34 | $0 | $0 | 34 | 06-25-2024 |
$3.34 | $3.29 | $3.34 | $3.43 | $3.27 | 1,882 | 06-24-2024 |
$3.1 | $3.2 | $3.1 | $3.2 | $3.1 | 4,366 | 06-21-2024 |
$3.225 | $0 | $3.225 | $0 | $0 | 123 | 06-20-2024 |
News, Short Squeeze, Breakout and More Instantly...
Genenta Science S.p.A. Company Name:
GNTA Stock Symbol:
NASDAQ Market:
Genenta Science S.p.A. Website:
A look at the top 10 most actives in the United States Onconetix Inc. (ONCO) rose 46.5% to $0.2183 on volume of 404,016,812 shares NVIDIA Corporation (NVDA) rose 2.6% to $121.09 on volume of 317,123,916 shares PROSHARES TRUST (SQQQ) rose 1.5% to $8.23 on volume of 207,449,647 shares Max...
MILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, announces that ...